Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
PLoS One ; 14(9): e0221823, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31490947

RESUMEN

OBJECTIVE: Studies suggest that parenteral MTX may be more efficacious than the oral form at equivalent doses for the treatment of rheumatoid arthritis. We carried out a meta-analysis to compare the efficacy of oral versus parenteral MTX in RA. METHODS: PubMed, Web of Science and Embase were systematically searched from inception to June 8th 2017 and reviewed following PRISMA 2009 guidelines, by two independent reviewers. To be included, trials had to study adults with RA randomized to the same dose of either oral or parenteral MTX. The primary endpoint was ACR20 at 6 months. Intention-to-treat analysis results were used when possible. Data from direct comparisons between oral and parenteral methotrexate quantitatively analyzed using maximum likelihood random effects meta-analysis. Relative treatment effects were generated as an odds ratio [OR] (OR>1 indicated a benefit for parenteral therapy). RESULTS: The search yielded 357 papers or abstracts. After review of titles or abstracts and full text papers, we found 4 that met inclusion criteria with 703 patients randomized. Dose of MTX started at 15mg/week and increased up to 25mg/week. The summary OR for achieving ACR20 using parenteral vs. oral MTX was 3.02 (95% CI 1.41, 6.46), with no significant difference in the risk for all adverse events. CONCLUSION: Parenteral MTX therapy had significantly higher odds than oral MTX of achieving reduction in disease activity. We propose that parenteral MTX is more effective than weekly oral MTX; its widespread use may lead to better control of disease and a decrease in demand for biologic agents.


Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Metotrexato/administración & dosificación , Administración Oral , Humanos , Resultado del Tratamiento
2.
FASEB J ; 24(9): 3160-70, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20385618

RESUMEN

Cutaneous malignant melanoma remains a therapeutic challenge, and patients with advanced disease have limited survival. Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and it may show promise as an antimelanoma modality. However, high melanin levels in melanomas can adversely affect PDT effectiveness. Herein the extent of melanin contribution to melanoma resistance to PDT was investigated in a set of melanoma cell lines that markedly differ in the levels of pigmentation; 3 new bacteriochlorins successfully overcame the resistance. Cell killing studies determined that bacteriochlorins are superior at (LD(50) approximately 0.1 microM) when compared with controls such as the FDA-approved Photofrin (LD(50) approximately 10 microM) and clinically tested LuTex (LD(50) approximately 1 microM). The melanin content affects PDT effectiveness, but the degree of reduction is significantly lower for bacteriochlorins than for Photofrin. Microscopy reveals that the least effective bacteriochlorin localizes predominantly in lysosomes, while the most effective one preferentially accumulates in mitochondria. Interestingly all bacteriochlorins accumulate in melanosomes, and subsequent illumination leads to melanosomal damage shown by electron microscopy. Fluorescent probes show that the most effective bacteriochlorin produces significantly higher levels of hydroxyl radicals, and this is consistent with the redox properties suggested by molecular-orbital calculations. The best in vitro performing bacteriochlorin was tested in vivo in a mouse melanoma model using spectrally resolved fluorescence imaging and provided significant survival advantage with 20% of cures (P<0.01).


Asunto(s)
Melanoma/tratamiento farmacológico , Fotoquimioterapia/métodos , Porfirinas/síntesis química , Porfirinas/uso terapéutico , Animales , Línea Celular Tumoral , Masculino , Ratones , Ratones Endogámicos C57BL , Microscopía Electrónica de Transmisión , Microscopía Fluorescente , Estructura Molecular , Porfirinas/química
3.
Trop Doct ; 40(1): 5-8, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19850608

RESUMEN

The outcome of hernia repair in patients with cirrhosis remains poor when compared to non-cirrhotics. The aim of our study was to evaluate the outcome of hernia repair in cirrhotic patients at our tertiary care hospital located in a developing country. A total of 61 patients with cirrhosis underwent hernia repair from January 2001 to December 2007 at our hospital. The mean age of the patients was 52 years and there were 30 males. Early postoperative complications were noted in 20 (33%) patients including two mortalities. The incidence of early complications was higher (71%) in patients with Child class C cirrhosis as compared to patients with either Child class A or B cirrhosis (21%), and the difference was statistically significant (P < 0.001). Except in emergency circumstances, surgery in Child class C patients may either be delayed until the patient is medically optimized or performed early before liver disease progresses to severe decompensation.


Asunto(s)
Hernia Abdominal/cirugía , Cirrosis Hepática/complicaciones , Complicaciones Posoperatorias/epidemiología , Adulto , Países en Desarrollo , Femenino , Hernia Abdominal/complicaciones , Hospitales , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Pakistán/epidemiología , Complicaciones Posoperatorias/mortalidad , Mallas Quirúrgicas/estadística & datos numéricos , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA